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Abstract 
Background: Autologous tolerogenic dendritic cells (tolDC) are a promising therapeutic strategy for inflammatory 
arthritis (IA) as they can regulate autoantigen-specific T cell responses. Here, we investigated two outstanding priori-
ties for clinical development: (i) the suitability of using heat-shock proteins (HSP), abundant in inflamed synovia, as 
surrogate autoantigens to be presented by tolDC and (ii) identification of functional biomarkers that confirm tolDC 
regulatory activity.
Methods: Cell proliferation dye-labelled human peripheral blood mononuclear cells of IA (rheumatoid arthritis (RA) 
and psoriatic arthritis (PsA)) patients or healthy donors were cultured with HSP40-, HSP60- and HSP70-derived pep-
tides or recall antigens (e.g. tuberculin purified protein derivative (PPD)) in the presence or absence of tolDC or control 
DC for 9 days. Functional characteristics of proliferated antigen-specific T-cells were measured using flow cytometry, 
gene expression profiling and cytokine secretion immunoassays. Repeated measures analysis of variance (ANOVA) 
with Bonferroni correction for comparisons between multiple groups and paired Student t test for comparisons 
between two groups were used to determine significance.
Results: All groups showed robust  CD4+ T-cell responses towards one or more HSP-derived peptide(s) as assessed 
by a stimulation index > 2 (healthy donors: 78%, RA: 73%, PsA: 90%) and production of the cytokines IFNγ, IL-17A and 
GM-CSF. Addition of tolDC but not control DC induced a type 1 regulatory (Tr1) phenotype in the antigen-specific 
 CD4+ T-cell population, as identified by high expression of LAG3, CD49b and secretion of IL-10. Furthermore, tolDC 
inhibited bystander natural killer (NK) cell activation in a TGFβ dependent manner.
Conclusions: HSP-specific  CD4+ T-cells are detectable in the majority of RA and PsA patients and can be converted 
into Tr1 cells by tolDC. HSP-loaded tolDC may therefore be suitable for directing T regulatory responses to antigens 
in inflamed synovia of IA patients. Tr1 markers LAG3, CD49b and IL-10 are suitable biomarkers for future tolDC clinical 
trials.
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Background
Rheumatoid arthritis (RA) arises from a breakdown in 
self-tolerance leading to aberrant immune responses 
to autoantigens. Current treatments involve chronic 
immunosuppression in a non-antigen specific manner. 
Although these treatments can be effective at alleviat-
ing symptoms they do not provide a cure and the asso-
ciated general immunosuppression can cause unwanted 
side effects (e.g. increased susceptibility to infection and 
certain cancers). An alternative approach are treatments 
that reinstate self-tolerance, leading to long-term remis-
sion whilst leaving protective immunity intact.
An emerging tolerogenic strategy is the administra-
tion of tolerogenic dendritic cells (tolDC). These cells 
act by inhibiting T-cell mediated pathology, for exam-
ple through the induction of regulatory T-cells (Treg) 
[1, 2]. We recently conducted a clinical trial of autolo-
gous tolDC treatment in both RA and psoriatic arthri-
tis (PsA) patients, confirming the safety and feasibility 
of this approach [3]. However, two critical and related 
issues were highlighted. The first relates to identification 
of the optimal target (auto)antigen(s). Because defini-
tive arthritogenic autoantigens have not been identified, 
for our clinical trial we pragmatically ‘loaded’ tolDC 
with autologous synovial fluid, based on data suggesting 
a content of relevant patient-specific autoantigens [4]. 
However, without knowledge of the targeted antigen(s)’ 
identity it was not possible to measure modulation of the 
antigen-specific T-cell response. The second issue is the 
lack of suitable biomarkers. Because tolDC act in a highly 
targeted manner, it is imperative to monitor changes in 
antigen-specific T-cells, rather than measuring systemic 
immune markers. Loading of tolDC with known anti-
gens will enable immune monitoring in a highly specific 
manner. Thus, future therapeutic studies with tolDC can 
be greatly improved by loading tolDC with relevant and 
known antigens, facilitating immune monitoring at the 
antigen-specific level and defining biomarkers of tolDC 
effectiveness.
We recently suggested to load tolDC with the surro-
gate self-antigens heat-shock proteins (HSPs) [5]. HSPs 
are molecular chaperone proteins highly expressed in 
inflamed tissue. Indeed, the expression of HSP40, HSP60 
and HSP70 family members is upregulated in the synovial 
tissue of RA patients [6–9] and in the inflamed tissues of 
patients with other autoimmune diseases like multiple 
sclerosis, atherosclerosis, juvenile dermatomyositis and 
juvenile idiopathic arthritis [10–14]. Moreover, adop-
tive transfer of HSP-specific Treg effectively suppressed 
established disease in a murine autoimmune arthritis 
model. Subsequent deletion of these donor HSP-specific 
Tregs completely reversed  the inhibition of disease pro-
gression, indicating disease suppression was induced by 
HSP-specific Tregs and not via bystander suppression 
[15]. Thus, it is likely that directing a regulatory T-cell 
response to a non-disease inducing antigen present in the 
diseased tissue is sufficient to dampen down pathogenic 
autoimmune responses.
To this aim, we (1) assessed the presence and pheno-
type of HSP-specific T-cells in RA and PsA patients and 
healthy donors; (2) investigated the ability of tolDC to 
induce a regulatory phenotype in HSP-specific T-cells, 
and (3) identified suitable biomarkers for the identifi-
cation of tolDC-modulated T-cells that can be used for 
imminent clinical trials.
Methods
The minimum information about tolerogenic antigen 
presenting cells (MITAP) checklist was followed for the 
preparation of this paper [16].
Peptides and antigens
HSP40 peptide: DnaJP1: QKRAAYDQYGHAAFE, HSP60 
peptides: p1: GEALSTLVVNKIRGT and p3: PYILLVS-
SKVSTVKD, HSP70 peptide: B29: VLRIVNEPTAAALAY 
and a negative control peptide A5: RQAILTLQTSSSEPR 
(Genscript). Whole antigens that were used were tuber-
culin purified protein derivative (PPD; Statens Serum 
Institut) and Candida albicans (CA; Soluprick; Alk).
Isolation of cells
Human blood samples were obtained from healthy con-
trols (HC) and treatment-naïve patients with recent 
onset arthritis (PsA and RA). Samples were collected 
with informed consent and following a favourable ethi-
cal opinion from local ethics committees. Peripheral 
blood mononuclear cells (PBMC; from 40  ml EDTA 
blood per donor) were isolated as previously described 
[17]. Monocytes were positively selected from PBMC 
using anti-CD14 microbeads (Miltenyi Biotec) according 
to manufacturer’s protocol with one minor change: 10 µl 
instead of 20  µl anti-CD14 beads per 1 × 107 cells was 
used for cell isolation. CD14-depleted PBMC (hereafter 
referred to as ‘PBMC’) were collected from the column 
flow-through and stored for 1 week at − 80  °C in FCS 
(Gibco) with 10% DMSO (Sigma) and were used for the 
measurement of HSP-specific T cell responses and the 
DC/PBMC co-culture experiments (see below).
Establishment of tolDC
Immediately after isolation, monocytes were cultured in 
24 wells plates (Corning) at 0.5 × 106 cells/ml (total 1 ml/
well) for 7 days in CellGenix DC medium (CellGenix) 
containing penicillin (100 U/ml), streptomycin (100  μg/
ml), GM-CSF (50 ng/ml; Immunotools) and IL-4 (50 ng/
ml; Immunotools). During this period cells were kept at 
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37  °C with 5%  CO2. On day 3, half of the medium was 
substituted by fresh (warm) medium containing GM-
CSF (100 ng/ml) and IL-4 (100 ng/ml). For the generation 
of tolDC, dexamethasone (1  μM; Sigma) was added on 
days 3 and 6 and 1,25-dihydroxyvitamin D3 (Calcitriol; 
0.1  nM; Tocris) and monophosphoryllipid A (MPLA) 
(1.0 μg/ml; Invivogen) were added only on day 6. Imma-
ture DC (imDC) were cultured in the presence of GM-
CSF (50 ng/ml) and IL-4 (50 ng/ml). On day 7, 24 h after 
the last treatment, DC were harvested and washed exten-
sively before functional assays were performed. DC were 
then resuspended at 4 × 105 cells/ml in X-VIVO-15. DC 
phenotype was checked using flow cytometry and was 
consistent with tolDC exhibiting a semi-mature pheno-
type, expressing low levels of CD83, intermediate levels 
of CD86 and high levels of HLA-DR and TLR2 (data not 
shown).
Measurement of HSP‑specific T cell responses
PBMC were thawed, washed and labelled with 0.2  μM 
carboxyfluorescein succinimidyl ester (CFSE; eBiosci-
ence) or 0.2 μM cell proliferation dye eFluor-450 (CTV; 
eBioscience) in PBS for 10 min at 37 °C. CFSE/CTV was 
quenched with 10% human serum (HS; Sigma) in HBSS 
(Lonza). Cells were resuspended at 2 × 106 cells/ml in 
X-VIVO-15 medium (Lonza) supplemented with 4% HS 
(final concentration 2%) and plated at 2 × 105 cells per 
well (96 wells; round bottom; Corning). For each peptide 
eight wells were prepared. Peptides were added at 10 µg/
ml. Cells were cultured for 9 days at 37 °C with 5%  CO2. 
At the end of the culture, supernatants were collected 
for cytokine determination. Depletion of CD14 from 
PBMC did not hamper detection of HSP-specific T cell 
responses (data not shown).
DC/PBMC co‑cultures
CFSE or CTV-labelled PBMC were resuspended at 
4 × 106 cells/ml in X-VIVO-15 medium (Lonza) supple-
mented with 8% HS (final concentration 2%) and plated 
at 2 × 105 cells per well (96 wells; round bottom; Corn-
ing). tolDC or, as a control, imDC were added in a 1:10 
ratio (i.e. 2 × 104/well), in the absence or presence of PPD 
(1 µg/ml) CA (1 µg/ml) or a cocktail of the HSP-peptides 
(HSP40 DnaJP; HSP60 p1 and p3; HSP70 B2; all at 4 µg/
ml) Cells were cultured for 6 (IL-10 secretion) or 9 days 
(all other measurements) at 37 °C with 5%  CO2. TGF-βRI 
(ALK5) inhibitor (SB-505124; 1  µM; Sigma) was added 
where indicated. At the end of the culture, supernatants 
were collected for cytokine determination.
Flow cytometry
For cell surface staining: cells were washed in flow 
cytometry buffer (PBS (Lonza) supplemented with 3% 
fetal calf serum (FCS; Gibco), 1  mM EDTA (Fisher Sci-
entific) and 0.01% sodium azide (Sigma)) before incu-
bating them for 30  min on ice in flow cytometry buffer 
containing antibodies and 4 µg/ml human immunoglob-
ulin (Ig)G (Grifols). Cells were washed and resuspended 
in flow cytometry buffer before analysis. For intracellular 
cytokine staining (ICS): cells were first stimulated with 
PMA (50 ng/ml) and ionomycin (1 μg/ml) for 5 h in the 
presence of brefeldin A (1 μg/ml; all from Sigma Aldrich) 
at 37  °C, 5%  CO2. Cells were then surface stained as 
described before, washed in flow cytometry buffer and 
fixed/permeabilised using cytofix/cytoperm buffer (BD 
Biosciences) for 30 min on ice. Cells were washed twice 
in 1× perm wash buffer (BD Biosciences) and stained 
for 30 min in 1× perm wash buffer containing antibod-
ies and 8% mouse serum. Cells were washed once in 1× 
perm wash buffer and once in flow cytometry buffer 
before resuspending them in flow cytometry buffer. Data 
were collected on an LSRfortessa X20 (BD Biosciences) 
and analysed using FlowJo (Tree Star Inc). Additional 
file 1: Table S1 depicts antibodies and live/dead dyes used 
for analysis.
RNA isolation and gene expression analysis
Cells from the PPD-DC/PBMC co-cultures were har-
vested and a total of 100,000  CFSE−CD4+DAPI− cells 
per sample were sorted into RLT buffer (Qiagen) sup-
plemented with 1% β-mercaptoethanol (Sigma) using a 
FACSAria-fusion sorter (BD Biosciences). Lysates were 
stored for up to 4 months at − 80 °C before isolation of 
RNA. RNA was isolated using an RNeasy Micro Kit (Qia-
gen; including DNase step) according to the manufac-
turer’s protocol. A total of 100 ng of RNA was used for 
gene expression profiling by the nCounter technology 
platform (NanoString; Human Immunology Panel), per-
formed according to the manufacturer’s protocol. Data 
was analysed using nSolver™ Analysis Software version 
4.0 and R.
IL‑10 secretion
Cells from PPD-DC/PBMC co-cultures were harvested 
on day 6 and a minimum of 25,000  CFSE−CD4+ (unfrac-
tionated proliferated  CD4+ T-cells from control-PPD cul-
tures) or  CFSE−CD4+LAG3+CD49b+ (proliferated Tr1 
cells from tolDC-PPD cultures) sorted into X-VIVO-15 
with 20% HS, using a FACSAria-fusion sorter. Sorted 
cells were rested for 2 days in X-VIVO-15 supplemented 
with 2% HS and 10 IU/ml of IL-2 (Proleukin; 25,000 cells/
well; 96-well round-bottom). Cells were subsequently 
washed and restimulated with 10 µg/ml platebound anti-
CD3 (OKT3; Biolegend) and 1 µg/ml soluble anti-CD28 
(CD28.2; Biolegend) in X-VIVO-15 supplemented with 
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2% HS (total 100  µl; 96-well flat-bottom). Supernatants 
were collected after 72 h for cytokine determination.
Cytokine secretion
Cytokine production was determined in supernatants 
by Meso Scale Discovery (MSD; U-Plex (IL-10, IFNγ, 
IL-4, IL-17A, GM-CSF) or by sandwich ELISA from BD 
(IL-10).
Statistical analysis
The following statistical analyses were performed 
using Prism 5: repeated measures analysis of variance 
(ANOVA) with Bonferroni correction for comparisons 
between multiple groups, paired Student t-test for com-
parisons between two groups.
Results
Pro‑inflammatory HSP‑specific T‑cells are present in IA 
patients
Our initial studies investigated whether immunodomi-
nant pan-DR-binding peptides from bacterial HSP40 
(dnaJP1), mycobacterial (myc)-HSP60 (p1 and p3) and 
myc-HSP70 (B29) [14, 15, 18] could be recognised by 
peripheral blood  CD4+ T-cells of healthy donors and 
IA patients (Table  1). We included both RA and PsA 
patients, because patients from both these IA groups 
participated in the phase I tolDC safety trial [3].
As shown in Fig. 1b, 78% of healthy donors, 73% of RA 
patients and 90% of PsA patients responded to at least 
one of the HSP peptides tested (Fig.  1b; see ‘All HSP’ 
which depicts the best HSP response for each donor). 
In the majority of cases, donors responded to one HSP 
only, but in around 10% of cases there was a detectable 
response to all four HSP peptides (Additional file 2: Fig 
S1).
To study the inflammatory nature of HSP-specific 
T-cell responses, we measured the secretion of the pro-
inflammatory cytokines IFNγ, GM-CSF, IL-17A and IL-4 
and the anti-inflammatory cytokine IL-10 in the super-
natants of the HSP cultures. PBMC from both healthy 
donors and RA/PsA patients produced significant lev-
els of pro-inflammatory cytokines in response to HSP 
(Fig. 1c).
TolDC induce a Tr1 phenotype in antigen‑specific T‑cells
The T-cell modulatory effects of human tolDC are usu-
ally studied in (tol)DC/T-cell co-culture models. How-
ever, because tolDC need to be able to regulate T-cell 
responses in the context of other immune cells, we 
assessed whether tolDC could regulate autologous  CD4+ 
T-cells in the antigen-specific PBMC culture system 
described above. To this aim, we initially used the recall 
antigen PPD. T-cell responses to PPD were assessed 
in the absence or presence of tolDC. As a control, we 
used another DC population with known, but unsta-
ble, tolerogenic function—immature monocyte-derived 
DC (imDC). Mature monocyte-derived DC as a control 
were also considered, but we found that these mature DC 
induced very high background (i.e. no antigen added) 
proliferation of CD4, CD8 and NK cells, which was not 
the case when imDC or tolDC were added to the PBMC 
cultures (data not shown). We compared the immune-
related gene-expression profile of PPD-specific T-cells 
activated in the absence or presence of tolDC or imDC. 
The gene expression profiles of the differentially acti-
vated PPD-specific T-cell groups clustered well together, 
indicating clear differences between treatment groups 
at the mRNA level (Fig.  2a). We identified 83 differen-
tially expressed genes (DEGs) from a total of 579 genes 
in PPD-specific T-cells activated in the presence of tolDC 
(tolDC-PPD T-cells) as compared to PPD-specific T-cells 
activated in the absence of monocyte-derived DC (con-
trol PPD T-cells) (Benjamini–Hochberg false discovery 
rate 10%). Of these 83 genes, 24 DEGs were also found in 
tolDC-PPD T-cells as compared to PPD-specific T-cells 
activated in the presence of imDC (imDC-PPD T-cells). 
Ten additional DEGs could be identified in tolDC-PPD 
T-cells as compared to imDC-PPD T-cells (Fig.  2b and 
Additional file 3: Table S2).
Among the tolDC-PPD versus control PPD T-cell iden-
tified DEGs, 20 genes could either be identified as type 1 
regulatory T-cells (Tr1)-specific genes or genes that have 
been described as inducers of Tr1-specific genes (Fig. 2c, 
[19–30]).
Recently, Gagliani et  al. [19], described two surface 
antigens, LAG3 and CD49b, as being highly and stably 
expressed on Tr1 cells. Moreover, co-expression of only 
these two surface proteins allowed for the identifica-
tion of Tr1 cells. To confirm that tolDC induce a Tr1 
phenotype in PPD-specific T-cells, we measured the 
co-expression of LAG3 and CD49b and several other 
Tr1-specific proteins identified in the gene expression 
analysis, by flow cytometry. TolDC induced significant 
Table 1 Characteristics of RA and PsA patients and healthy 
donors
Except where indicated otherwise, values are the median (interquartile range)
CRP C-reactive protein
RA (n = 19) PsA (n = 10) Healthy (n = 19)
Age, years 66 (60–70) 50 (34–56) 45 (29–52)
Sex, % females 68 50 63
Duration of symp-
toms, weeks
12 (7–40) 17 (8–37) –
CRP, g/l 27 (9–53) 6 (5–19) –
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upregulation of the LAG3, TIM3, CD86 and PD-1 
proteins as compared to control PPD cultures and the 
combined expression of LAG3 and CD49b could iden-
tify tolDC-induced PPD-specific Tr1 cells (Fig. 2d).
A hallmark of Tr1 cells is the high secretion of IL-10 
in the absence of IL-4 [19, 31–33]. As shown in Fig. 3a, 
significantly higher levels of IL-10 were produced in the 
tolDC-PPD cultures as compared to the imDC-PPD or 
a
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Fig. 1 Inflammatory arthritis (IA) patients have pro-inflammatory HSP-specific  CD4+ T-cells. Cell proliferation dye (CFSE/CTV)-labelled PBMC of 
healthy controls and IA patients were cultured with pan-DR-binding HSP peptides: DnaJP1, HSP60p1, HSP60p2 and B29 for 9 days. a, b Percentage 
of CFSE/CTV-negative live  CD4+ T-cells was measured using flow cytometry. Gating example (a) and graphs with stimulation index (SI) b are shown. 
SI was measured by dividing the percentage of CFSE/CTV−  CD4+ T-cells of HSP culture by the percentage of CFSE/CTV−  CD4+ T-cells medium 
control (i.e. no peptide added) culture. SI > 2 was considered as increased above background proliferation. ‘All HSP’ indicates best HSP response per 
donor. c Cytokine secretion in culture supernatants was measured using MSD immunoassay. Left circle indicates cytokine concentration in medium 
control culture, right square indicates cytokines concentration in HSP culture. Two-tailed paired Student T-test was used. *p ≤ 0.05, **p ≤ 0.01
Page 6 of 12Spiering et al. J Transl Med          (2019) 17:375 
control PPD cultures. We furthermore showed that re-
stimulation of sorted, proliferated  LAG3+CD49b+CD4+ 
Tr1 cells produced high levels of IL-10 but no IL-4 
(Fig. 3b).
Overall, these data clearly indicate that tolDC induce 
a Tr1 phenotype in autologous antigen-specific  CD4+ 
T-cells.
TolDC induce a Tr1 phenotype in HSP‑specific T‑cells of RA 
patients
Since we established that HSP-specific T-cells are pro-
inflammatory in both patients and healthy controls, and 
that the co-expression of LAG3 and CD49b can be used 
to identify tolDC-activated antigen-specific Tr1 cells, 
we used these markers to study whether tolDC induced 
a Tr1 phenotype in HSP-specific T-cells of IA patients. 
tolDC-activated HSP T-cells had significantly higher 
levels of LAG3/CD49b, coinciding with decreased lev-
els of GM-CSF and IFNγ and increased IL-10 produc-
tion as compared to control PPD T-cells (Fig. 4a, b and 
d). In addition, tolDC also induced a Tr1 phenotype in 
response to a third (control) antigen, Candida albicans 
(CA; Fig.  4c). Thus, tolDC are capable of inducing Tr1 
responses in autologous antigen-specific  CD4+ T-cells, 
irrespective of the antigen.
As our antigen-specific T-cell activation model using 
PBMC allowed us to check the behaviour of other types 
of immune cells, we had observed high levels of NK-cell 
proliferation. Interestingly, bystander NK-cell prolif-
eration was largely inhibited by tolDC in HSP-cultures 
(Fig. 5a, b) and CA-cultures (Fig. 5c). We have previously 
shown that tolDC produce high amounts of TGFβ [17]. 
It is known that TGFβ can hamper NK-cell prolifera-
tion and activation [34, 35] and we therefore investigated 
whether blocking of the TGFβ-receptor could reverse the 
tolDC-induced suppression of NK-cell activation. Indeed, 
addition of SB-505124, a small molecule inhibitor of 
TGF-βRI, restored NK-cell proliferation in tolDC-CA 
cultures (Fig. 5d).
Altogether, our findings demonstrate that tolDC can 
convert pro-inflammatory antigen-specific  CD4+ T-cells 
in IA (RA and PsA) patients into anti-inflammatory Tr1 
cells, which are characterised by expression of LAG3/
CD49b and IL-10 production. In addition, tolDC-derived 
TGFβ blocks bystander NK-cell activation.
Discussion
This study focused on two key questions that require 
elucidation before further tolDC clinical trials in RA can 
commence. First, as the idea behind tolDC therapy is to 
dampen the autoreactive T cell response, tolDC will need 
‘loading’ with an appropriate disease-relevant antigen. 
Second, as tolDC act in a highly targeted manner, it is 
necessary to have suitable biomarkers that reflect modifi-
cation of antigen-specific  CD4+ T-cell responses in order 
to monitor tolDC efficiency in clinical trials.
There has been debate over the last few years about 
the need for loading of tolDC with a disease-relevant 
antigen for treatment in autoimmune diseases. Several 
animal studies have shown that disease remission can 
be achieved by treatment with unpulsed tolDC [36, 37], 
suggesting that tolDC may be able to pick up the rel-
evant antigens in vivo. Indeed, phase I safety trials with 
unloaded tolDC have been completed for diabetes and 
Crohn’s disease [38, 39].  The risk, however, with using 
non-antigen-pulsed tolDC in vivo, is that (i) it is uncer-
tain whether tolDC pick up and present appropriate 
antigen(s) and (ii) the identity of the presented antigen is 
unknown. Thus, if it is unknown which antigens are pre-
sented by tolDC, monitoring the antigen-specific T-cells 
response is not possible. In addition, other animal stud-
ies have shown that loading of tolDC is crucial for their 
therapeutic potential. For example, we and others have 
shown that loading of tolDC with type II collagen was 
required for disease remission in the collagen-induced 
arthritis model [40–42]. The same is true for a mouse 
model of multiple sclerosis. Myelin oligodendrocyte gly-
coprotein-pulsed tolDC performed significantly better 
than unpulsed tolDC [43, 44]. We and others have there-
fore used autoantigen-pulsed tolDC for our phase I clini-
cal safety trials [3, 45].
Fig. 2 tolDC induce a Tr1 phenotype in antigen-specific  CD4+ T cells. Cell proliferation dye (CFSE/CTV)-labelled PBMC of healthy controls were 
cultured with the recall antigen PPD and tolDC (tol), imDC (im) or without addition of any type of moDC (−) for 9 days. a–d 100,000 CFSE/CTV− 
life  CD4+ T-cells were sorted by FACS. Cell were then lysed and gene expression determined by the NanoString nCounter platform. a Principal 
component analysis (PCA) plot showing clustering of the different groups. PC1: principal component 1; PC2 principal component 2. b Venn 
diagram showing genes differentially expressed (BH P ≤ 0.1) with at least a 1.5-fold change for control (no moDC) PPD T-cells (left circle) and 
imDC-PPD T-cells (right circle) compared to tolDC-PPD T-cells. The numbers in the circles indicate the modulated genes for each condition. The 
grey area represents the overlap between both conditions. d Heat map of Tr1-related gene expression levels that were significantly (BH P ≤ 0.1) 
differentially expressed with at least a 1.5-fold change in tolDC-PPD T-cells compared to control (no moDC) PPD T-cells. e Percentages of LAG3, 
CD49b, TIM3, CD86 and PD-1 in CFSE/CTV− live  CD4+ T-cells were measured using flow cytometry. Repeated measures analysis of variance was 
used. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
(See figure on next page.)
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However, the search for a common antigen to load tolDC 
for treatment of autoimmune diseases, like RA, has been 
a challenge. Here, we describe the use of HSP peptides as 
surrogate self-antigens to load tolDC. Since HSPs are highly 
expressed in the inflamed tissues of patients with numer-
ous autoimmune diseases [6–14], HSP peptides would be 
ideal antigens for tolDC loading, not only for the treatment 
of RA, but also for tolDC-based treatments of other auto-
immune diseases. Because these HSP antigens are only 
expressed in inflamed tissues, the regulatory actions of 
tolDC-induced HSP-specific Tr1 cells will be targeted to 
the site of inflammation only. Interestingly, we found that 
nearly 80% of both healthy individuals and RA/PsA patients 
have  CD4+ T-cell-reactivity to the HSP peptides tested, 
indicating the (expected) promiscuity of these peptides.
The next step was to identify how tolDC alter the anti-
gen-specific  CD4+ T-cell response. As with all novel ther-
apeutic approaches, suitable biomarkers are vital for the 
measurement of treatment efficiency. Using several anti-
gens, including the HSP peptides, we showed that tolDC 
induce a clear Tr1 phenotype in antigen-specific  CD4+ 
T-cells, with high expression of the Tr1 molecules LAG3 
and CD49b and the anti-inflammatory cytokine IL-10 
[19, 46]. With these findings, future immune monitoring 
could significantly be improved by measuring the Tr1 
markers LAG3/CD49b on HSP-specific—or other dis-
ease-relevant antigen-specific—MHC II  tetramer+  CD4+ 
T-cells.
An important additional finding we report here is 
the striking reduction of bystander NK-cell prolifera-
tion in tolDC/PBMC co-cultures. The synovial fluid of 
RA patients contains high levels of NK cells and they 
have been shown to aggravate cytokine imbalance and 
inflammation in rheumatic joints [47–50]. NK cell pro-
liferation is mainly dependent on the cytokines IL-2, 
IL-7 and IL-15 [51, 52] and can be hampered by fac-
tors like  H2O2, soluble CD25 and TGFβ. We found that 
tolDC did not inhibit NK cell proliferation via IL-2, 
IL-15, soluble CD25 or  H2O2, (data not shown), but 
found that NK cell proliferation could be restored by 
blocking TGFβ receptor signalling. This finding sup-
ports our previous notion that enhanced production of 
TGFβ is important for tolDC function [17] and that the 
tolerogenic role of tolDC in vivo might not be limited 
to their effect on the  CD4+ T-cell population. Instead, 
tolDC could have a direct anti-inflammatory effect on 
the pathogenic immune cells present in the arthritic 
joints.
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Fig. 3 tolDC induce functional IL-10-producing antigen-specific Tr1 cells. Cell proliferation dye (CFSE/CTV)-labelled PBMC of healthy controls 
were cultured with the recall antigen PPD and tolDC (tol), imDC (im) or without addition of any type of moDC (−) for 9 (a) or 6 (b) days. a Cytokine 
secretion in culture supernatants was measured using ELISA. Repeated measures ANOVA was used. b CFSE/CTV− live  CD4+ (total  CD4+) and 
 CD4+LAG3+CD49b+ T-cells (Tr1) were sorted, rested with 10 IU/ml of IL-2 for 2 days and restimulated by plate bound anti-CD3 (10 μg/ml) and 
soluble anti-CD28 (1 μg/ml) for 3 days. Cytokine secretion in culture supernatants was measured using MSD immunoassay. One-tailed paired 
Student T-test was used. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
Fig. 4 tolDC tolerise the HSP-specific T-cell response. Cell proliferation dye (CFSE/CTV)-labelled PBMC of IA patients were cultured with an 
HSP-peptide pool (HSP60p1, HSP60p2 and B29; 4 μg/ml per peptide) (a, b, d) or CA (1:1000) (c) and tolDC (tolDC) or without addition of any type 
of moDC (-) for 9 days. a–c Percentages and ratios of LAG3 and CD49b in CFSE/CTV− life  CD4+ T-cells were measured using flow cytometry. Gating 
strategy (a) HSP-peptide graphs (b) and CA graphs (c) are shown. Ratios were measured by dividing the percentage of CFSE/CTV−  CD4+ T-cells 
of tolDC cultures by the percentage of CFSE/CTV−  CD4+ T-cells of non-moDC cultures. d Percentages of GM-CSF, IFNγ, IL-17A and IL-10 in CFSE/
CTV− life  CD4+ T-cells were measured after stimulation with PMA (50 ng/ml) ionomycin (1 μg/ml) and brefeldin A (1 μg/ml for 5 h by using flow 
cytometry. One-tailed (IL-10 and LAG3/CD49b) or two-tailed (all other) paired Student T-test was used. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
(See figure on next page.)
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Conclusions
tolDC induce a Tr1 phenotype in antigen-specific 
T-cells of both healthy individuals and IA (RA and PsA) 
patients. The normally pro-inflammatory HSP-specific 
 CD4+ T-cells of IA patients can be converted into anti-
inflammatory Tr1 cells and bystander NK-cell prolifera-
tion is hampered due to high levels of tolDC-derived 
TGFβ. Thus, HSP-pulsed tolDC may be a promis-
ing tool for the restoration of immune tolerance in IA 
patients. Indeed, we (WE and FB) are currently prepar-
ing for a phase I trial with HSP70 peptide B29-pulsed 
tolDC in rheumatoid arthritis patients.
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